Clinical profile and outcome of Henoch Schonlein purpura in a tertiary care hospital in South India


  • Shanavas Abbas Department of Pediatrics, Government Medical College, Thiruvananthapuram, Kerala, India
  • Geetha S. Department of Pediatrics, Government Medical College, Thiruvananthapuram, Kerala, India
  • Deepthi R.V. Department of Nephrology, CMC, Vellore, Tamil Nadu, India
  • Jubin Kamar Department of Pediatrics, Government Medical College, Thiruvananthapuram, Kerala, India
  • Susan Uthup Department of Pediatrics, Government Medical College, Thiruvananthapuram, Kerala, India



Clinical features, HSP, Treatment


Background: Henoch Schonlein purpura (HSP) is the most common systemic vasculitis in children. It is an immunoglobulin A (IgA) mediated systemic small-vessel vasculitis, with IgA deposition in vessel walls leading to symptoms involving the skin, joints, intestines, and kidneys. The objective of present study was to identify and describe the clinical profile, pattern of joint involvement, histopathological features, treatment modalities and complications of Henoch Schonlein purpura.

Methods: 52 children less than 12 years diagnosed to have Henoch Schonlein Purpura according to the European League against Rheumatism criteria were included in the study. All patients were subjected to detailed history taking and thorough examination. The clinical features, investigations, management and complications of the disease were studied. Descriptive statistics was used to analyse the results.

Results: The common clinical features were palpable purpura (100%) followed by arthritis (66%) and abdominal pain (50%). Renal manifestations were in the form of hematuria in 12% of the patients. Skin biopsy was done in 25 patients of which 19 had findings suggestive of Henoch Schonlein purpura. Steroids were used in 42% of patients. The severity of illness was associated with lower mean age, arthritis, leg edema and stool occult blood.

Conclusions: The clinical features of Henoch Schonlein purpura in the population were different from the previously published studies. Renal involvement was less common. The short-term outcome of the patients were satisfactory. 


Behrman RE, Kliegman RM, Arvin AM. Nelson Textbook of Pediatrics. 20th ed. Philadelphia, Saunders; 2008:1043-5.

Duvuru G, Stone JH. Henoch-Schönlein purpura. In: Imboden JB, Hellmann DB, Stone JH, editors. Current diagnosis and treatment. Rheumatology. 3rd ed. New York, NY: McGraw-Hill; 2013.

Trapani S, Micheli A, Grisolia F, Resti M, Chiappini E, Falcini F et al. Henoch Schonlein Purpura in childhood: epidemiological and clinical analysis of 150 cases over a 5-year period and review of literature. Semin Arthritis Rheum. 2005;35(3):143-53.

Ozen S, Pistorio A, Iusan SM, Bakkaloglu A, Herlin T, Brik R. EULAR/PRINTO/PRES criteria for Henoch-Schonlein purpura, childhood polyarteritis nodosa, childhood WEGENER granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: final classification criteria. Ann Rheum Dis. 2010;69:798-806.

Nong BR, Huang YF, Chuang CM, Liu CC, Hsieh KS. Fifteen-year experience of children with Henoch-Schonlein purpura in Southern Taiwan, 1991-2005. J Microbiol Immunol Infect. 2007;40(4):371–6.

Anil M, Aksu N, Kara OD, Bal A, Anil AB, Yavascan O et al. Henoch-Schonlein purpura in children from western Turkey: a retrospective analysis of 430 cases. Turk J Pediatr. 2009;51(5):429-36.

Rostoker G. Schönlein-Henoch purpura in children and adults: diagnosis, pathophysiology and management. BioDrugs. 2001;15(2):99-138.

Yang YH, Hung CF, Hsu CR, Wang LC, Chuang YH, Lin YT et al. A nationwide survey on epidemiological characteristics of childhood Henoch-Schönlein purpura in Taiwan. Rheumatology (Oxford). 2005;44:618-22.

Saulsbury FT. Henoch-Schönlein purpura in children: report of 100 patients and review of the literature. Medicine. 1999;78:395-409.

Association CM. Medicine - Guide of Clinical Diagnosis and Treatment. Peking: People’s Medical Publishing House; 2007.

Wang X, Zhu Y, Gao L, Wei S, Zhen Y, Ma Q. Henoch-Schönlein purpura with joint involvement: Analysis of 71 cases. Pediatric Rheum. 2016;14:20.

Connolly B, O’Halpin D. Sonographic evaluation of the abdomen in henoch-schonlein purpura. Clin Radiol. 1994;49(5):320-3.

Choong CK, Beasley SW. Intra-abdominal manifestations of Henoch-Schönlein purpura. J Paediatr Child Health. 1998 Oct; 34(5):405-9.

Chen JY, Mao JH. Henoch-Schonlein purpura nephritis in children: incidence, pathogenesis and management. World J Pediatr. 2015;11(1):29-34.

Mir S, Yavascan O, Mutlubas F, Yeniay B, Sonmez F. Clinical outcome in children with Henoch-Schonlein nephritis. Pediatr Nephrol. 2007;22(1):64-70.

Saulsbury FT. Clinical update: Henoch-Schonlein purpura. Lancet. 2007;369(9566):976-8.

Nickavar A, Mehrazma M, Lahouti A. Clinicopathologic correlations in Henoch-Schonlein nephritis. Iran J Kidney Dis. 2012;6(6):437-40.

Trnka P. Henoch-Schönlein purpura in children. J Paediatr Child Health. 2013;49(12):995-1003.

Tabel Y, Inanc FC, Dogan DG, Elmas AT. Clinical features of children with Henoch-Schonlein purpura: risk factors associated with renal involvement. Iran J Kidney Dis. 2012;6(4):269-74.

Bluman J, Goldman RD. Henoch Schönlein purpura in children: limited benefit of corticosteroids. Can Fam Physician. 2014;60(11):1007-10.

Jauhola O, Ronkainen J, Koskimies O, Ala-Houhala M, Arikoski P, Hölttä T et al. Outcome of Henoch-Schönlein purpura 8 years after treatment with a placebo or prednisone atdisease onset. Pediatr Nephrol. 2012;27(6):933-9.

Huang FJ. The effect of oral corticosteroids in children with Henoch-Schönlein purpura. Mod Pract Med. 2014;26(12):1532-4.

Weiss PF, Feinstein JA, Luan X, Burnham JM, Feudtner C. Effects of corticosteroid on Henoch-Schönlein purpura: a systematic review. Pediatrics. 2007;120(5):1079-87.

Chartapisak W, Opastirakul S, Hodson EM, Willis NS, Craig JC. Interventions for preventing and treating kidney disease in Henoch-Schönlein purpura (HSP) Cochrane Database Syst Rev. 2009;(3):CD005128.

Jauhola O, Ronkainen J, Koskimies O, Ala-Houhala M, Arikoski P, Hölttä T et al. Clinical course of extrarenal symptoms in Henoch-Schonlein purpura: a 6-month prospective study. Arch Dis Child. 2010;95(11):871-6.

Lava SA, Peeters GG, Bianchetti MG, Simonetti BG, Simonetti GD, Milani GP. Posterior reversible encephalopathy syndrome in Henoch-Schönlein purpura, Rheumatol Int. 2017;37(3):461-3.






Original Research Articles